human il 27 Search Results


92
R&D Systems anti human il27r
Figure 1 Mutations of <t>IL27R</t> that enhance the transforming activity of IL27R
Anti Human Il27r, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human il27r/product/R&D Systems
Average 92 stars, based on 1 article reviews
anti human il27r - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

93
R&D Systems mouse anti human il 27ra mab
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Mouse Anti Human Il 27ra Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human il 27ra mab/product/R&D Systems
Average 93 stars, based on 1 article reviews
mouse anti human il 27ra mab - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

94
R&D Systems human recombinant il 27
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Human Recombinant Il 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human recombinant il 27/product/R&D Systems
Average 94 stars, based on 1 article reviews
human recombinant il 27 - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

93
Elabscience Biotechnology elisa kit
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Elisa Kit, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elisa kit/product/Elabscience Biotechnology
Average 93 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

91
R&D Systems human il 27
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Human Il 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il 27/product/R&D Systems
Average 91 stars, based on 1 article reviews
human il 27 - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

93
R&D Systems il 27
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Il 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 27/product/R&D Systems
Average 93 stars, based on 1 article reviews
il 27 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

92
R&D Systems flow cytometry anti human il27r
FIGURE 1. <t>sIL-27Ra</t> is released from differ- ent primary human cell types. (A) Purified CD4+
Flow Cytometry Anti Human Il27r, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flow cytometry anti human il27r/product/R&D Systems
Average 92 stars, based on 1 article reviews
flow cytometry anti human il27r - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

90
R&D Systems anti wsx 1 mab
Analysis of IL-27 and IL-27 receptor expression in placental tissues. (a) Representative Western blot analysis of IL-27 receptor subunits <t>WSX-1</t> in placental tissues. The first three are representative of samples of normal pregnancy (N) group and the last is from the PE group. (b)–(i) Immunohistochemical staining of IL-27 and WSX-1 in the placental tissues. (b) and (d) show the immunostaining of IL-27 in normal control (N) group; (c) and (e) show the immunostaining of IL-27 in preeclampsia (PE) group. (f) and (h) show the immunostaining of the WSX-1 in normal control (N) group; (g) and (i) show the immunostaining of WSX-1 in preeclampsia (PE) group. β -Actin was used as protein control to ensure an equal amount of loaded protein. Original magnification: 100x for c, f, g, and h; 400x for d, e, h, and i. All experiments were performed in three independent replicates.
Anti Wsx 1 Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti wsx 1 mab/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti wsx 1 mab - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

85
R&D Systems goat biotinylated polyclonal anti human il 27 ab
Analysis of IL-27 and IL-27 receptor expression in placental tissues. (a) Representative Western blot analysis of IL-27 receptor subunits <t>WSX-1</t> in placental tissues. The first three are representative of samples of normal pregnancy (N) group and the last is from the PE group. (b)–(i) Immunohistochemical staining of IL-27 and WSX-1 in the placental tissues. (b) and (d) show the immunostaining of IL-27 in normal control (N) group; (c) and (e) show the immunostaining of IL-27 in preeclampsia (PE) group. (f) and (h) show the immunostaining of the WSX-1 in normal control (N) group; (g) and (i) show the immunostaining of WSX-1 in preeclampsia (PE) group. β -Actin was used as protein control to ensure an equal amount of loaded protein. Original magnification: 100x for c, f, g, and h; 400x for d, e, h, and i. All experiments were performed in three independent replicates.
Goat Biotinylated Polyclonal Anti Human Il 27 Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat biotinylated polyclonal anti human il 27 ab/product/R&D Systems
Average 85 stars, based on 1 article reviews
goat biotinylated polyclonal anti human il 27 ab - by Bioz Stars, 2026-06
85/100 stars
  Buy from Supplier

93
R&D Systems wsx1
Quantification of biomarkers.
Wsx1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wsx1/product/R&D Systems
Average 93 stars, based on 1 article reviews
wsx1 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

Image Search Results


Figure 1 Mutations of IL27R that enhance the transforming activity of IL27R

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 1 Mutations of IL27R that enhance the transforming activity of IL27R

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Activity Assay

Figure 2 Mutant IL27R proteins exhibit enhanced transforming activity compared with IL27R-WT

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 2 Mutant IL27R proteins exhibit enhanced transforming activity compared with IL27R-WT

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Mutagenesis, Activity Assay

Figure 3 Cells expressing transforming IL27R mutants display increased activation of signalling proteins

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 3 Cells expressing transforming IL27R mutants display increased activation of signalling proteins

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Expressing, Activation Assay

Figure 4 F523S and F523A mutations of IL27R do not enhance the transforming activity of IL27R-WT

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 4 F523S and F523A mutations of IL27R do not enhance the transforming activity of IL27R-WT

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Activity Assay

Figure 5 The IL27R- mutant exhibits enhanced homodimeric complex formation

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 5 The IL27R- mutant exhibits enhanced homodimeric complex formation

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Mutagenesis

Figure 6 Comparison of the transforming properties of IL27R proteins to known transforming haemopoietic mutations

Journal: Biochemical Journal

Article Title: Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity

doi: 10.1042/bj20110351

Figure Lengend Snippet: Figure 6 Comparison of the transforming properties of IL27R proteins to known transforming haemopoietic mutations

Article Snippet: Anti-human IL27R (TCCR/WSX-1) antibody (R&D Systems) was conjugated to Alexa Fluor® 647 using an Alexa Fluor® 647 antibody labelling kit (Molecular Probes).

Techniques: Comparison

FIGURE 1. sIL-27Ra is released from differ- ent primary human cell types. (A) Purified CD4+

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 1. sIL-27Ra is released from differ- ent primary human cell types. (A) Purified CD4+

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques:

FIGURE 2. ELISA analysis of sIL-27Ra in the sera of healthy indi- viduals. (A) Levels of sIL-27Ra were measured by ELISA in the sera from healthy individuals. (B) The correlation between sIL-27Ra and IL-27 se- rum levels is shown. Although a logarithmic scale is used, linear regression was calculated using the actual values. (C) Sera from six pregnant women, collected at various times during pregnancy (6–10 sera per time point), were tested by sIL-27Ra ELISA. The mean values (6SEM) are represented. (D) Sera from four nonpregnant healthy individuals (Da–d) and four pregnant women (De–h) were tested in a sandwich ELISA using the indicated Abs as capture Abs and biotinylated anti-human IL-27 Ab as detection Ab.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 2. ELISA analysis of sIL-27Ra in the sera of healthy indi- viduals. (A) Levels of sIL-27Ra were measured by ELISA in the sera from healthy individuals. (B) The correlation between sIL-27Ra and IL-27 se- rum levels is shown. Although a logarithmic scale is used, linear regression was calculated using the actual values. (C) Sera from six pregnant women, collected at various times during pregnancy (6–10 sera per time point), were tested by sIL-27Ra ELISA. The mean values (6SEM) are represented. (D) Sera from four nonpregnant healthy individuals (Da–d) and four pregnant women (De–h) were tested in a sandwich ELISA using the indicated Abs as capture Abs and biotinylated anti-human IL-27 Ab as detection Ab.

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques: Enzyme-linked Immunosorbent Assay, Sandwich ELISA

FIGURE 3. Biochemical characterization of sIL- 27Ra. Lysates from COS7 cells transiently transfected with vector control or vector expressing IL-27RaV5His (A), and anti–IL-27Ra immunoprecipitates from the lysate of IL-27RaV5His–transfected COS7 cells before or after N-glycanase treatment (B), were analyzed by immunoblot using anti–IL-27Ra Ab. (C) Concentrated culture supernatant from KMH2 cells (left) or human sera (right) was submitted to immunoprecipitation with goat or mouse anti–IL-27Ra Abs, followed by protein G beads, or with anti–IL-27Ra beads, as indicated, and analyzed by anti–IL-27Ra immunoblot. (D) Treatment of anti–IL-27Ra immunoprecipitate from KMH2 cul- ture supernatant with N-glycanase causes a shift in the apparent molecular mass of sIL-27Ra from 90/70 to 60 kDa. Cross-reacting IgH is indicated by an asterisk. Kilodaltons of molecular size markers are reported on the left.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 3. Biochemical characterization of sIL- 27Ra. Lysates from COS7 cells transiently transfected with vector control or vector expressing IL-27RaV5His (A), and anti–IL-27Ra immunoprecipitates from the lysate of IL-27RaV5His–transfected COS7 cells before or after N-glycanase treatment (B), were analyzed by immunoblot using anti–IL-27Ra Ab. (C) Concentrated culture supernatant from KMH2 cells (left) or human sera (right) was submitted to immunoprecipitation with goat or mouse anti–IL-27Ra Abs, followed by protein G beads, or with anti–IL-27Ra beads, as indicated, and analyzed by anti–IL-27Ra immunoblot. (D) Treatment of anti–IL-27Ra immunoprecipitate from KMH2 cul- ture supernatant with N-glycanase causes a shift in the apparent molecular mass of sIL-27Ra from 90/70 to 60 kDa. Cross-reacting IgH is indicated by an asterisk. Kilodaltons of molecular size markers are reported on the left.

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques: Transfection, Plasmid Preparation, Control, Expressing, Western Blot, Immunoprecipitation

FIGURE 4. Role of metalloproteases in the production of sIL-27Ra. (A) COS7 cells were cotransfected with GFP vector and pcDNA3 control vector or pcDNA3 encoding IL-27RaV5His. Two days after transfection, cells were stained with isotype control (filled gray histogram) or anti–IL-27Ra (bold line) Abs and analyzed by FACS. Staining observed in GFP-positive cells is shown. (B) Cell culture supernatants from transfected COS7 cells were tested by Western blot for detection of sIL-27R. Only Abs recognizing the extracellular domain of IL-27Ra, but not its intracellular C terminus (V5 mAb), detected sIL-27Ra. (C) Cell culture supernatants from IL-27RaV5His–transfected COS7 cells, incubated for the indicated times with GM6001, TAPI-0 (both at 50 mM), or DMSO control, were tested by sIL-27Ra ELISA. No sIL-27Ra was detected in the culture supernatant from vector control-transfected COS7 cells. (D) Cell lysates from COS7 cells collected 48 h after transfection were analyzed by immunoblot with anti-V5 Ab to monitor IL-27RaV5His expression levels. On a longer exposure, a smaller band that was weaker in the presence of metalloprotease inhibitors and might correspond to the transmembrane and intracellular domains was observed (data not shown). One representative experiment of two to three is shown in (A)–(D). (E) KMH2 cells were incubated for 3 d with various con- centrations of GM6001, TAPI-0, or DMSO. Levels of sIL-27Ra measured by ELISA in the culture supernatants and cell numbers determined by trypan blue exclusion are shown as the mean 6 SEM of relative levels of three independent experiments. (F) Purified CD4+ T cells were stimulated for 5 d with CD2/CD3/ CD28 beads and IL-2 and various concentrations of GM6001, TAPI-0, or DMSO. Relative levels of sIL-27Ra and cell numbers observed in four independent experiments performed with different donors are shown. Inhibitor doses .25 mM were not used in CD4+ T cells because they resulted in cell toxicity. (G) Cell membrane IL-27Ra expression (mIL-27Ra) was analyzed by FACS in activated CD4+ T cells cultured for 5 d in the presence of GM6001, TAPI-0 (both at 25 mM), or DMSO. The mean fluorescence intensity of mIL-27Ra staining is indicated. (H) The mean fluorescence intensity of mIL-27Ra staining observed in GM6001 or TAPI-0–treated CD4+ T cells relative to that observed in the DMSO control is shown as mean 6 SEM of four independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 4. Role of metalloproteases in the production of sIL-27Ra. (A) COS7 cells were cotransfected with GFP vector and pcDNA3 control vector or pcDNA3 encoding IL-27RaV5His. Two days after transfection, cells were stained with isotype control (filled gray histogram) or anti–IL-27Ra (bold line) Abs and analyzed by FACS. Staining observed in GFP-positive cells is shown. (B) Cell culture supernatants from transfected COS7 cells were tested by Western blot for detection of sIL-27R. Only Abs recognizing the extracellular domain of IL-27Ra, but not its intracellular C terminus (V5 mAb), detected sIL-27Ra. (C) Cell culture supernatants from IL-27RaV5His–transfected COS7 cells, incubated for the indicated times with GM6001, TAPI-0 (both at 50 mM), or DMSO control, were tested by sIL-27Ra ELISA. No sIL-27Ra was detected in the culture supernatant from vector control-transfected COS7 cells. (D) Cell lysates from COS7 cells collected 48 h after transfection were analyzed by immunoblot with anti-V5 Ab to monitor IL-27RaV5His expression levels. On a longer exposure, a smaller band that was weaker in the presence of metalloprotease inhibitors and might correspond to the transmembrane and intracellular domains was observed (data not shown). One representative experiment of two to three is shown in (A)–(D). (E) KMH2 cells were incubated for 3 d with various con- centrations of GM6001, TAPI-0, or DMSO. Levels of sIL-27Ra measured by ELISA in the culture supernatants and cell numbers determined by trypan blue exclusion are shown as the mean 6 SEM of relative levels of three independent experiments. (F) Purified CD4+ T cells were stimulated for 5 d with CD2/CD3/ CD28 beads and IL-2 and various concentrations of GM6001, TAPI-0, or DMSO. Relative levels of sIL-27Ra and cell numbers observed in four independent experiments performed with different donors are shown. Inhibitor doses .25 mM were not used in CD4+ T cells because they resulted in cell toxicity. (G) Cell membrane IL-27Ra expression (mIL-27Ra) was analyzed by FACS in activated CD4+ T cells cultured for 5 d in the presence of GM6001, TAPI-0 (both at 25 mM), or DMSO. The mean fluorescence intensity of mIL-27Ra staining is indicated. (H) The mean fluorescence intensity of mIL-27Ra staining observed in GM6001 or TAPI-0–treated CD4+ T cells relative to that observed in the DMSO control is shown as mean 6 SEM of four independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques: Plasmid Preparation, Control, Transfection, Staining, Cell Culture, Western Blot, Incubation, Enzyme-linked Immunosorbent Assay, Expressing, Membrane

FIGURE 5. Natural sIL-27Ra antagonizes IL-27 signaling. (A) Concentrated cell culture supernatant of KMH2 cells was submitted to immuno- precipitation with control or anti–IL-27Ra Abs, in the absence or presence of 100 ng rIL-27. Immunoprecipitates (lanes 1–4) and a fraction of su- pernatant before immunoprecipitation (lane 5) were analyzed by anti–IL-27Ra and anti-EBI3 immunoblots. (B and C) rIL-27 was preincubated for 15 min at 37˚C with various concentrations of rIL-27R-Fc or gp130-Fc fusion proteins, or purified natural sIL-27Ra, before addition to BL2 cells for 15 min. Cell lysates were analyzed for STAT1 activation with anti–phospho-STAT1 Ab and subsequently with STAT1 Ab to monitor STAT1 levels. (D) Similar experiment was conducted using IFN-g in place of IL-27. (E) Inhibition of IL-27 binding to BL2 cells. rIL-27 (2 ng) was preincubated or not with purified natural sIL-27Ra (2 ng) before incubation with BL2 cells. IL-27 binding was measured by FACS. One representative experiment of two to three is shown.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 5. Natural sIL-27Ra antagonizes IL-27 signaling. (A) Concentrated cell culture supernatant of KMH2 cells was submitted to immuno- precipitation with control or anti–IL-27Ra Abs, in the absence or presence of 100 ng rIL-27. Immunoprecipitates (lanes 1–4) and a fraction of su- pernatant before immunoprecipitation (lane 5) were analyzed by anti–IL-27Ra and anti-EBI3 immunoblots. (B and C) rIL-27 was preincubated for 15 min at 37˚C with various concentrations of rIL-27R-Fc or gp130-Fc fusion proteins, or purified natural sIL-27Ra, before addition to BL2 cells for 15 min. Cell lysates were analyzed for STAT1 activation with anti–phospho-STAT1 Ab and subsequently with STAT1 Ab to monitor STAT1 levels. (D) Similar experiment was conducted using IFN-g in place of IL-27. (E) Inhibition of IL-27 binding to BL2 cells. rIL-27 (2 ng) was preincubated or not with purified natural sIL-27Ra (2 ng) before incubation with BL2 cells. IL-27 binding was measured by FACS. One representative experiment of two to three is shown.

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques: Cell Culture, Immunoprecipitation, Control, Western Blot, Activation Assay, Inhibition, Binding Assay, Incubation

FIGURE 6. Analysis of sIL-27Ra and IL-27 levels in the sera of CD patients. Serum levels of sIL-27Ra (A) and IL-27 (B) were determined by ELISA in 52 CD patients and 28 healthy individuals. The correlation between sIL-27Ra and IL-27 serum levels (C) and the molar ratio between IL-27 and sIL-27Ra serum values (D) are shown. Although a logarithmic scale is used in (C), linear regression was calculated using the actual values.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: A soluble form of IL-27Rα is a natural IL-27 antagonist.

doi: 10.4049/jimmunol.1303435

Figure Lengend Snippet: FIGURE 6. Analysis of sIL-27Ra and IL-27 levels in the sera of CD patients. Serum levels of sIL-27Ra (A) and IL-27 (B) were determined by ELISA in 52 CD patients and 28 healthy individuals. The correlation between sIL-27Ra and IL-27 serum levels (C) and the molar ratio between IL-27 and sIL-27Ra serum values (D) are shown. Although a logarithmic scale is used in (C), linear regression was calculated using the actual values.

Article Snippet: To investigate whether sIL27Ra could form complexes with IL-27 in the sera, we developed an ELISA by using mouse anti-human IL-27Ra mAb or a control isotype mAb as coating Abs, and goat biotinylated polyclonal anti-human IL-27 Ab (R&D Systems) as detection Ab.

Techniques: Enzyme-linked Immunosorbent Assay

Analysis of IL-27 and IL-27 receptor expression in placental tissues. (a) Representative Western blot analysis of IL-27 receptor subunits WSX-1 in placental tissues. The first three are representative of samples of normal pregnancy (N) group and the last is from the PE group. (b)–(i) Immunohistochemical staining of IL-27 and WSX-1 in the placental tissues. (b) and (d) show the immunostaining of IL-27 in normal control (N) group; (c) and (e) show the immunostaining of IL-27 in preeclampsia (PE) group. (f) and (h) show the immunostaining of the WSX-1 in normal control (N) group; (g) and (i) show the immunostaining of WSX-1 in preeclampsia (PE) group. β -Actin was used as protein control to ensure an equal amount of loaded protein. Original magnification: 100x for c, f, g, and h; 400x for d, e, h, and i. All experiments were performed in three independent replicates.

Journal: Mediators of Inflammation

Article Title: IL-27 Activates Human Trophoblasts to Express IP-10 and IL-6: Implications in the Immunopathophysiology of Preeclampsia

doi: 10.1155/2014/926875

Figure Lengend Snippet: Analysis of IL-27 and IL-27 receptor expression in placental tissues. (a) Representative Western blot analysis of IL-27 receptor subunits WSX-1 in placental tissues. The first three are representative of samples of normal pregnancy (N) group and the last is from the PE group. (b)–(i) Immunohistochemical staining of IL-27 and WSX-1 in the placental tissues. (b) and (d) show the immunostaining of IL-27 in normal control (N) group; (c) and (e) show the immunostaining of IL-27 in preeclampsia (PE) group. (f) and (h) show the immunostaining of the WSX-1 in normal control (N) group; (g) and (i) show the immunostaining of WSX-1 in preeclampsia (PE) group. β -Actin was used as protein control to ensure an equal amount of loaded protein. Original magnification: 100x for c, f, g, and h; 400x for d, e, h, and i. All experiments were performed in three independent replicates.

Article Snippet: Sections were incubated with anti-IL-27 mAb (Abcam115671, HK) and anti-WSX-1 mAb (RD AF1479), diluted in 5% (wt/vol) nonfat milk for 16 h at 4°C.

Techniques: Expressing, Western Blot, Immunohistochemical staining, Staining, Immunostaining

IL-27 and IL-27 receptor was expressed in HTR-8/SVneo cells and it upregulated CXCL10 and IL-6. (a) RNA and protein expression for WSX-1. (b) RNA and protein expression of gp130. From the left to the right lane, respectively, are Hct116 (human colon cancer cells), Skov3 (ovarian carcinoma cells), and HTR-8/SVneo. Hct116 and Skov3 were used as control. GAPDH was used as protein control to ensure an equal amount of loaded protein. (c) Effects of IL-27 (50 ng/mL) on the mRNA expression of inflammatory mediators. Kinetic gene expressed of CXCL10 (d) and IL-6 (e) in HTR-8/SVneo cells under stimulated with IL-27. * P < 0.05, ** P < 0.01, and *** P < 0.001 when compared between groups denoted by horizontal lines ( n = 3). (f) CXCL10 protein levels after the stimulation of IL-27 (0–50 ng/mL) in cell supernatant of HTR-8/SVneo (0–30 h). (g) IL-6 protein expression after the stimulation of IL-27 (0–50 ng/mL) in cell supernatant of HTR-8/SVneo (0–48 h). * P < 0.05, ** P < 0.01, and *** P < 0.001 when comparing the level at the starting time point. All experiments were performed in three independent replicates.

Journal: Mediators of Inflammation

Article Title: IL-27 Activates Human Trophoblasts to Express IP-10 and IL-6: Implications in the Immunopathophysiology of Preeclampsia

doi: 10.1155/2014/926875

Figure Lengend Snippet: IL-27 and IL-27 receptor was expressed in HTR-8/SVneo cells and it upregulated CXCL10 and IL-6. (a) RNA and protein expression for WSX-1. (b) RNA and protein expression of gp130. From the left to the right lane, respectively, are Hct116 (human colon cancer cells), Skov3 (ovarian carcinoma cells), and HTR-8/SVneo. Hct116 and Skov3 were used as control. GAPDH was used as protein control to ensure an equal amount of loaded protein. (c) Effects of IL-27 (50 ng/mL) on the mRNA expression of inflammatory mediators. Kinetic gene expressed of CXCL10 (d) and IL-6 (e) in HTR-8/SVneo cells under stimulated with IL-27. * P < 0.05, ** P < 0.01, and *** P < 0.001 when compared between groups denoted by horizontal lines ( n = 3). (f) CXCL10 protein levels after the stimulation of IL-27 (0–50 ng/mL) in cell supernatant of HTR-8/SVneo (0–30 h). (g) IL-6 protein expression after the stimulation of IL-27 (0–50 ng/mL) in cell supernatant of HTR-8/SVneo (0–48 h). * P < 0.05, ** P < 0.01, and *** P < 0.001 when comparing the level at the starting time point. All experiments were performed in three independent replicates.

Article Snippet: Sections were incubated with anti-IL-27 mAb (Abcam115671, HK) and anti-WSX-1 mAb (RD AF1479), diluted in 5% (wt/vol) nonfat milk for 16 h at 4°C.

Techniques: Expressing

Quantification of biomarkers.

Journal: Frontiers in Immunology

Article Title: Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner

doi: 10.3389/fimmu.2025.1550699

Figure Lengend Snippet: Quantification of biomarkers.

Article Snippet: The following antibodies and their respective fluorochrome were used: CD38 (Fluorochrome PE-Cy7; Cat. # 560677, BD Biosciences, Franklin Lakes, NJ, USA), isotype control (Fluorochrome PE-Cy7; Cat. # 557872, BD Biosciences), CD130/GP130 (Fluorochrome AF647, Cat. # 564151, BD Biosciences), isotype control (Fluorochrome AF647, Cat. # 557714, BD Biosciences), WSX1 (Fluorochrome PE; Cat. # FAB14791PO2, R&D Systems), and isotype control (Fluorochrome PE; Cat. # IC0041P, R&D Systems).

Techniques:

Detection of WSX and gp130 on M2 macrophages using FACS. The surface expression of WSX1 and gp130 on M2 macrophages was assessed by flow cytometry as described in the Materials and Methods. (A) The left and right panels show WSX1 and gp130 (CD130) staining, respectively. The staining pattern of isotype control antibodies is shown in gray line, and black indicates the protein of interest. The x-axis and y-axis show fluorescence intensity and cell counts, respectively. The percentages in the panels indicate the percentage of cells expressing WSX1 or gp130 in the samples. Data are representative of three independent experiments with similar outcomes. (B) Flow cytometric analysis of M2 macrophages showing the expression of WSX1 and gp130 (CD130) from one donor M2 macrophages. (C) FACS analysis for WSX1 and gp130 expression on M2 cells was performed using three independent donor cells. Results indicated means ± SE (n = 3). FACS, fluorescence-activated cell sorting.

Journal: Frontiers in Immunology

Article Title: Interleukin-27-polarized HIV-resistant M2 macrophages are a novel subtype of macrophages that express distinct antiviral gene profiles in individual cells: implication for the antiviral effect via different mechanisms in the individual cell-dependent manner

doi: 10.3389/fimmu.2025.1550699

Figure Lengend Snippet: Detection of WSX and gp130 on M2 macrophages using FACS. The surface expression of WSX1 and gp130 on M2 macrophages was assessed by flow cytometry as described in the Materials and Methods. (A) The left and right panels show WSX1 and gp130 (CD130) staining, respectively. The staining pattern of isotype control antibodies is shown in gray line, and black indicates the protein of interest. The x-axis and y-axis show fluorescence intensity and cell counts, respectively. The percentages in the panels indicate the percentage of cells expressing WSX1 or gp130 in the samples. Data are representative of three independent experiments with similar outcomes. (B) Flow cytometric analysis of M2 macrophages showing the expression of WSX1 and gp130 (CD130) from one donor M2 macrophages. (C) FACS analysis for WSX1 and gp130 expression on M2 cells was performed using three independent donor cells. Results indicated means ± SE (n = 3). FACS, fluorescence-activated cell sorting.

Article Snippet: The following antibodies and their respective fluorochrome were used: CD38 (Fluorochrome PE-Cy7; Cat. # 560677, BD Biosciences, Franklin Lakes, NJ, USA), isotype control (Fluorochrome PE-Cy7; Cat. # 557872, BD Biosciences), CD130/GP130 (Fluorochrome AF647, Cat. # 564151, BD Biosciences), isotype control (Fluorochrome AF647, Cat. # 557714, BD Biosciences), WSX1 (Fluorochrome PE; Cat. # FAB14791PO2, R&D Systems), and isotype control (Fluorochrome PE; Cat. # IC0041P, R&D Systems).

Techniques: Expressing, Flow Cytometry, Staining, Control, Fluorescence, FACS